JP2024542984A - がんを治療および予防するためのピペリジニルピラジン－カルボキサミド化合物、およびｂｔｋを分解するためのピペリジニルピラジン－カルボキサミド化合物 - Google Patents

がんを治療および予防するためのピペリジニルピラジン－カルボキサミド化合物、およびｂｔｋを分解するためのピペリジニルピラジン－カルボキサミド化合物 Download PDF

Info

Publication number
JP2024542984A
JP2024542984A JP2024525065A JP2024525065A JP2024542984A JP 2024542984 A JP2024542984 A JP 2024542984A JP 2024525065 A JP2024525065 A JP 2024525065A JP 2024525065 A JP2024525065 A JP 2024525065A JP 2024542984 A JP2024542984 A JP 2024542984A
Authority
JP
Japan
Prior art keywords
compound
cancer
formula
certain embodiments
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525065A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542984A5 (enExample
Inventor
ジェイ． ブラウン，ロバート
ティー． サンズ，アーサー
Original Assignee
ニューリックス セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューリックス セラピューティクス，インコーポレイテッド filed Critical ニューリックス セラピューティクス，インコーポレイテッド
Publication of JP2024542984A publication Critical patent/JP2024542984A/ja
Publication of JP2024542984A5 publication Critical patent/JP2024542984A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024525065A 2021-10-26 2022-10-25 がんを治療および予防するためのピペリジニルピラジン－カルボキサミド化合物、およびｂｔｋを分解するためのピペリジニルピラジン－カルボキサミド化合物 Pending JP2024542984A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163263081P 2021-10-26 2021-10-26
US63/263,081 2021-10-26
US202263391671P 2022-07-22 2022-07-22
US63/391,671 2022-07-22
PCT/US2022/047767 WO2023076303A1 (en) 2021-10-26 2022-10-25 Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk

Publications (2)

Publication Number Publication Date
JP2024542984A true JP2024542984A (ja) 2024-11-19
JP2024542984A5 JP2024542984A5 (enExample) 2025-09-09

Family

ID=84361163

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525065A Pending JP2024542984A (ja) 2021-10-26 2022-10-25 がんを治療および予防するためのピペリジニルピラジン－カルボキサミド化合物、およびｂｔｋを分解するためのピペリジニルピラジン－カルボキサミド化合物

Country Status (9)

Country Link
US (1) US12377106B2 (enExample)
EP (1) EP4422630A1 (enExample)
JP (1) JP2024542984A (enExample)
KR (1) KR20240090898A (enExample)
AU (1) AU2022379494A1 (enExample)
CA (1) CA3236073A1 (enExample)
IL (1) IL312357A (enExample)
MX (1) MX2024004899A (enExample)
WO (1) WO2023076303A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004191A (es) 2018-10-15 2021-05-27 Nurix Therapeutics Inc Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
US12582722B2 (en) 2019-02-13 2026-03-24 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
WO2021113557A1 (en) 2019-12-04 2021-06-10 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
CA3236073A1 (en) 2021-10-26 2023-05-04 Robert J. Brown Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070054355A1 (en) 2003-03-05 2007-03-08 Yuval Reiss Cbl-b polypeptides, complexes and related methods
WO2007072225A2 (en) 2005-12-01 2007-06-28 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2008033403A2 (en) 2006-09-13 2008-03-20 The Trustees Of Columbia University In The City Of New York Agents and methods to elicit anti-tumor immune response
AT506041A1 (de) 2007-12-10 2009-05-15 Univ Innsbruck Verfahren zur erhöhung der immunreaktivität
PL2242749T3 (pl) 2008-02-05 2013-09-30 Hoffmann La Roche Nowe pirydynony i pirydazynony
EP2440204B1 (en) 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
EP2566869B1 (en) 2010-05-07 2016-03-02 Gilead Connecticut, Inc. Pyridone and aza-pyridone compounds and methods of use
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
EP2471548A1 (de) 2010-12-28 2012-07-04 Apeiron Biologics AG siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
MX2014005282A (es) 2011-11-03 2014-05-30 Hoffmann La Roche Compuestos de 8-fluoroftalazin-1 (2h) -ona.
KR102668696B1 (ko) 2012-01-12 2024-05-29 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
WO2014040965A1 (en) 2012-09-13 2014-03-20 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
US9382246B2 (en) 2013-12-05 2016-07-05 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
MX2017015574A (es) 2015-06-02 2018-08-09 Pharmacyclics Llc Inhibidores de tirosina quinasa de bruton.
AU2016297362B2 (en) 2015-07-17 2020-04-16 Takeda Pharmaceutical Company Limited Oxadiazole derivatives useful as HDAC inhibitors
HUE066460T2 (hu) 2016-10-26 2024-08-28 Iovance Biotherapeutics Inc A kriokonzervált tumor infiltráló limfociták restimulációja
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
CA3042297A1 (en) 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
WO2018106870A1 (en) 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
EP3743063A4 (en) 2018-01-26 2021-10-20 Nurix Therapeutics, Inc. CBL-B INHIBITORS AND THEIR METHODS OF USE
EP3746426A4 (en) 2018-01-29 2021-12-29 Dana Farber Cancer Institute, Inc. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
CN112584852A (zh) * 2018-06-19 2021-03-30 百欧恩泰美国公司 新抗原及其用途
MX2021004191A (es) 2018-10-15 2021-05-27 Nurix Therapeutics Inc Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
US12582722B2 (en) 2019-02-13 2026-03-24 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
CA3136348A1 (en) 2019-04-09 2020-10-15 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
AU2020278592B2 (en) 2019-05-17 2024-10-10 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof
MX2021015675A (es) 2019-06-26 2022-02-03 Nurix Therapeutics Inc Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos.
AU2020320195A1 (en) 2019-07-30 2022-03-10 Nurix Therapeutics, Inc. Urea, amide, and substituted heteroaryl compounds for Cbl-b inhibition
EP4034140A1 (en) 2019-09-24 2022-08-03 Nurix Therapeutics, Inc. Cbl inhibitors and compositions for use in adoptive cell therapy
US20230024442A1 (en) 2019-11-08 2023-01-26 Nurix Therapeutics, Inc. Bifunctional compounds for grading btk via ubiquitin proteosome pathway
WO2021113557A1 (en) * 2019-12-04 2021-06-10 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
AU2022310182A1 (en) 2021-07-14 2024-02-01 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk with diminished imid activity
CN118019539A (zh) 2021-07-23 2024-05-10 纽力克斯治疗公司 用于降解BTK并具有增强的IMiD活性的双官能化合物
CA3236073A1 (en) 2021-10-26 2023-05-04 Robert J. Brown Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk

Also Published As

Publication number Publication date
EP4422630A1 (en) 2024-09-04
US12377106B2 (en) 2025-08-05
KR20240090898A (ko) 2024-06-21
AU2022379494A1 (en) 2024-05-30
US20230149416A1 (en) 2023-05-18
CA3236073A1 (en) 2023-05-04
IL312357A (en) 2024-06-01
MX2024004899A (es) 2024-05-24
WO2023076303A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
JP7741282B2 (ja) ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物
EP4069237B1 (en) Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
JP7745679B2 (ja) 置換された４－アミノイソインドリン－１，３－ジオン化合物、及びリンパ腫の治療のためのそれらの使用
JP2024542984A (ja) がんを治療および予防するためのピペリジニルピラジン－カルボキサミド化合物、およびｂｔｋを分解するためのピペリジニルピラジン－カルボキサミド化合物
EP3190889B1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
JP2024527567A (ja) Ｋｒａｓの阻害剤としての三環式化合物
CA2907751C (en) 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1h-pyrrolo[2,3-c]pyridine derivatives as nik inhibitors for the treatment of cancer
WO2020100027A1 (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
JP2019518059A (ja) ＰＩ３Ｋβ阻害剤としてのアザベンゾイミダゾール誘導体
CA2942751A1 (en) Macrocylic pyridine derivatives
CA2942636A1 (en) Macrocylic pyrimidine derivatives
CN108699080B (zh) 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物
WO2021224818A1 (en) Isoindolone compounds as hpk1 inhibitors
AU2017324281A1 (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-A]pyridinyl compounds, compositions and methods of use thereof
CN118475352A (zh) 用于治疗和预防癌症以及用于降解btk的哌啶基吡嗪-甲酰胺类化合物
RU2851298C2 (ru) Новые ингибиторы JAK1-киназ
HK40081936A (en) Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
TWI692476B (zh) 環丁基-咪唑啶酮化合物
BR122023025072A2 (pt) Usos de compostos bifuncionais para degradar btk por meio da via da ubiquitina-proteossoma
TW202602873A (zh) 新穎降解劑化合物及其用途
TW202421153A (zh) 細胞週期蛋白依賴性激酶７的抑制劑
HK40058692A (en) 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
OA20485A (en) IMIDAZO[4,5-C]pyridine derivatives as tolllike receptor agonsits
HK40029219A (en) Compounds as neurokinin-1 receptor antagonists and uses thereof
OA20310A (en) 2,3-dihydro-1H-pyrrolo[3,4-C] pyridin-1one derivatives as HPK1 inhibitors for the treatment of cancer.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250901